SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "L773:0020 7136 "

Sökning: L773:0020 7136

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
61.
  • Baglietto, Laura, et al. (författare)
  • DNA methylation changes measured in pre-diagnostic peripheral blood samples are associated with smoking and lung cancer risk
  • 2017
  • Ingår i: International Journal of Cancer. - 0020-7136. ; 140:1, s. 50-61
  • Tidskriftsartikel (refereegranskat)abstract
    • DNA methylation changes are associated with cigarette smoking. We used the Illumina Infinium HumanMethylation450 array to determine whether methylation in DNA from pre-diagnostic, peripheral blood samples is associated with lung cancer risk. We used a case-control study nested within the EPIC-Italy cohort and a study within the MCCS cohort as discovery sets (a total of 552 case-control pairs). We validated the top signals in 429 case-control pairs from another 3 studies. We identified six CpGs for which hypomethylation was associated with lung cancer risk: cg05575921 in the AHRR gene (p-valuepooled  = 4 × 10(-17) ), cg03636183 in the F2RL3 gene (p-valuepooled  = 2 × 10 (- 13) ), cg21566642 and cg05951221 in 2q37.1 (p-valuepooled  = 7 × 10(-16) and 1 × 10(-11) respectively), cg06126421 in 6p21.33 (p-valuepooled  = 2 × 10(-15) ) and cg23387569 in 12q14.1 (p-valuepooled  = 5 × 10(-7) ). For cg05951221 and cg23387569 the strength of association was virtually identical in never and current smokers. For all these CpGs except for cg23387569, the methylation levels were different across smoking categories in controls (p-valuesheterogeneity  ≤ 1.8 x10 (- 7) ), were lowest for current smokers and increased with time since quitting for former smokers. We observed a gain in discrimination between cases and controls measured by the area under the ROC curve of at least 8% (p-values ≥ 0.003) in former smokers by adding methylation at the 6 CpGs into risk prediction models including smoking status and number of pack-years. Our findings provide convincing evidence that smoking and possibly other factors lead to DNA methylation changes measurable in peripheral blood that may improve prediction of lung cancer risk.
62.
  • Balavarca, Yesilda, et al. (författare)
  • Performance of individual and joint risk stratification by an environmental risk score and a genetic risk score in a colorectal cancer screening setting
  • ????
  • Ingår i: International Journal of Cancer. - John Wiley & Sons. - 0020-7136.
  • Tidskriftsartikel (refereegranskat)abstract
    • Early detection of colorectal neoplasms can reduce the disease burden of colorectal cancer by timely intervention of individuals at high risk. Our aim was to evaluate a joint environmental-genetic risk score as a risk stratification tool for early detection of advanced colorectal neoplasm (ACRN). Known environmental risk factors and high-risk genetic loci were summarized into risk scores for ACRN in 1014 eligible participants of a screening study. The performances of single and joint environmental-genetic scores were evaluated with estimates and 95% confidence intervals (CI) of the absolute risk, relative risk and predictive ability using the area under the curve (AUC). Individuals with higher environmental risk scores showed increasing ACRN risk, with 3.1-fold for intermediate risk and 4.8-fold for very high risk, compared to the very low environmental risk group. Similarly, individuals with higher genetic risk scores showed increasing ACRN risk, with 2.2-fold for intermediate risk and 3.5-fold for very high risk, compared to the lowest genetic risk group. Moreover, the joint environmental–genetic score improved the ACRN risk stratification and showed higher predictive values (AUC = 0.64; 95%CI = 0.60–0.67) with substantial difference (p = 0.0002) compared to the single environmental score (0.58; 0.55–0.62). The integration of environmental and genetic factors looks promising for improving targeting individuals at high-risk of colorectal neoplasm. Applications in practical screening programs require optimization with additional genetic and other biomarkers involved in colorectal carcinogenesis.
  •  
63.
  • Baltzer, Nicholas, et al. (författare)
  • Risk stratification in cervical cancer screening by complete screening history : Applying bioinformatics to a general screening population
  • 2017
  • Ingår i: International Journal of Cancer. - 0020-7136 .- 1097-0215. ; 141:1, s. 200-209
  • Tidskriftsartikel (refereegranskat)abstract
    • Women screened for cervical cancer in Sweden are currently treated under a one-size-fits-all programme, which has been successful in reducing the incidence of cervical cancer but does not use all of the participants' available medical information. This study aimed to use women's complete cervical screening histories to identify diagnostic patterns that may indicate an increased risk of developing cervical cancer. A nationwide case-control study was performed where cervical cancer screening data from 125,476 women with a maximum follow-up of 10 years were evaluated for patterns of SNOMED diagnoses. The cancer development risk was estimated for a number of different screening history patterns and expressed as Odds Ratios (OR), with a history of 4 benign cervical tests as reference, using logistic regression. The overall performance of the model was moderate (64% accuracy, 71% area under curve) with 61-62% of the study population showing no specific patterns associated with risk. However, predictions for high-risk groups as defined by screening history patterns were highly discriminatory with ORs ranging from 8 to 36. The model for computing risk performed consistently across different screening history lengths, and several patterns predicted cancer outcomes. The results show the presence of risk-increasing and risk-decreasing factors in the screening history. Thus it is feasible to identify subgroups based on their complete screening histories. Several high-risk subgroups identified might benefit from an increased screening density. Some low-risk subgroups identified could likely have a moderately reduced screening density without additional risk.
  •  
64.
  • Bamia, Christina, et al. (författare)
  • Coffee, tea and decaffeinated coffee in relation to hepatocellular carcinoma in a European population : multicentre, prospective cohort study
  • 2015
  • Ingår i: International Journal of Cancer. - John Wiley & Sons. - 0020-7136. ; 136:8, s. 1899-1908
  • Tidskriftsartikel (refereegranskat)abstract
    • Inverse associations of coffee and/or tea in relation to hepatocellular carcinoma (HCC) risk have been consistently identified in studies conducted mostly in Asia where consumption patterns of such beverages differ from Europe. In the European Prospective Investigation into Cancer and nutrition (EPIC), we identified 201 HCC cases among 486,799 men/women, after a median follow-up of 11 years. We calculated adjusted hazard ratios (HRs) for HCC incidence in relation to quintiles/categories of coffee/tea intakes. We found that increased coffee and tea intakes were consistently associated with lower HCC risk. The inverse associations were substantial, monotonic and statistically significant. Coffee consumers in the highest compared to the lowest quintile had lower HCC risk by 72% [HR: 0.28; 95% confidence intervals (CIs): 0.16-0.50, p-trend < 0.001]. The corresponding association of tea with HCC risk was 0.41 (95% CI: 0.22-0.78, p-trend = 0.003). There was no compelling evidence of heterogeneity of these associations across strata of important HCC risk factors, including hepatitis B or hepatitis C status (available in a nested case-control study). The inverse, monotonic associations of coffee intake with HCC were apparent for caffeinated (p-trend = 0.009), but not decaffeinated (p-trend = 0.45) coffee for which, however, data were available for a fraction of subjects. Results from this multicentre, European cohort study strengthen the existing evidence regarding the inverse association between coffee/tea and HCC risk. Given the apparent lack of heterogeneity of these associations by HCC risk factors and that coffee/tea are universal exposures, our results could have important implications for high HCC risk subjects.
  •  
65.
  •  
66.
  • Bao, Cuiping, et al. (författare)
  • Diabetes in midlife and risk of cancer in late life : A nationwide Swedish twin study
  • 2018
  • Ingår i: International Journal of Cancer. - 0020-7136. ; 143:4, s. 793-800
  • Tidskriftsartikel (refereegranskat)abstract
    • The association between diabetes and cancer risk remains controversial. Hence, we examined whether midlife diabetes is related to the risk of cancer in late-life, and whether genetic and early-life environmental factors play a role in this association. This study included 25,154 twin individuals born in 1958 or earlier from the Swedish Twin Registry. Information on cancer diagnosis in late life (aged >= 65) during 1998-2014, was derived from the National Patient and Cancer Registries. Diabetes was ascertained based on self- or informant-reported history, patient registry and antidiabetic medication use. Midlife diabetes was defined when diabetes was diagnosed before 65 years. Data were analyzed following two strategies: (i) unmatched case-control analysis for all participants using generalized estimating equation (GEE) models, and (ii) co-twin control analysis for cancer-discordant twin pairs using conditional logistic regression. Overall, 1,766 (7.0%) had midlife diabetes and 5,293 (21.0%) had cancer in late-life. In multiadjusted GEE models, the odds ratios (95% CIs) of diabetes were 10.55 (2.95-37.67) for pharynx cancer, 5.78 (1.72-19.40) for small intestine cancer, 2.37 (1.14-4.91) for liver cancer and 0.48 (0.35-0.67) for prostate cancer. In people with diabetes, diabetes duration was dose-dependently associated with cancer risk. In conditional logistic regression analysis of 176 prostate cancer-discordant twin pairs, the association between midlife diabetes and prostate cancer in later life became stronger. Midlife diabetes increases the risk of pharynx, small intestine and liver cancers, but reduces prostate cancer risk in late life. Genetic and early-life environmental factors may partially contribute to the diabetes-prostate cancer association.
  •  
67.
  • Bao, Cuiping, et al. (författare)
  • Overweight in midlife and risk of cancer in late life : A nationwide Swedish twin study
  • 2019
  • Ingår i: International Journal of Cancer. - 0020-7136. ; 144:9, s. 2128-2134
  • Tidskriftsartikel (refereegranskat)abstract
    • Our study examined whether midlife overweight (body mass index [BMI] >= 25) is associated with late-life cancer risk and explored the role of genetic and early-life environmental factors in this association. The study included 14,766 individuals from the Swedish Twin Registry, whose midlife (30-50 years) height and weight were recorded. Information on cancer diagnoses in late life (>65 years) was derived from the National Patient Registry and Cancer Registry. Generalized estimating equation (GEE) models were used to analyze unmatched case-control data (controlled for the clustering of twins within a pair). A co-twin matched case-control analysis used conditional logistic regression to compare cancer-discordant twins. Of all participants, 3968 (26.9%) were overweight and 4253 (28.8%) had cancer. In multi-adjusted GEE models using normal-weight (BMI 18.5-24.9) participants as the reference group, overweight was related to higher risk of colon cancer (OR 1.36, 95% CI: 1.00-1.84, p = 0.049), liver cancer (OR 2.00, 95% CI: 1.11-3.62), cervix uteri cancer (OR 2.86, 95% CI: 1.19-6.91) and corpus uteri cancer (OR 1.78, 95% CI: 1.14-2.78) but lower risk of nonmelanoma skin cancer (OR 0.77, 95% CI: 0.66-0.90). In conditional logistic regression analysis, these associations were attenuated becoming nonsignificance. The difference in ORs from the unmatched and matched analyses was not significant. In conclusion, midlife overweight is associated with increased risk of late-life colon, liver and uterine cancer but reduced risk of late-life nonmelanoma skin cancer. Further investigations are warranted to explore the role of genetic and early-life environmental factors in these associations.
  •  
68.
  • Barash, Uri, et al. (författare)
  • Heparanase promotes glioma progression via enhancing CD24 expression
  • 2019
  • Ingår i: International Journal of Cancer. - WILEY. - 0020-7136 .- 1097-0215. ; 145:6, s. 1596-1608
  • Tidskriftsartikel (refereegranskat)abstract
    • Heparanase is an endo-beta-d-glucuronidase that cleaves heparan sulfate (HS) side chains of heparan sulfate proteoglycans. Compelling evidence tie heparanase levels with all steps of tumor formation including tumor initiation, growth, metastasis and chemo-resistance, likely involving augmentation of signaling pathways and gene transcription. In order to reveal the molecular mechanism(s) underlying the protumorigenic properties of heparanase, we established an inducible (Tet-on) system in U87 human glioma cells and applied gene array methodology in order to identify genes associated with heparanase induction. We found that CD24, a mucin-like cell adhesion protein, is consistently upregulated by heparanase and by heparanase splice variant devoid of enzymatic activity, whereas heparanase gene silencing was associated with decreased CD24 expression. This finding was further substantiated by a similar pattern of heparanase and CD24 immunostaining in glioma patients (Pearson's correlation; R = 0.66, p = 0.00001). Noteworthy, overexpression of CD24 stimulated glioma cell migration, invasion, colony formation in soft agar and tumor growth in mice suggesting that CD24 functions promote tumor growth. Likewise, anti-CD24 neutralizing monoclonal antibody attenuated glioma tumor growth, and a similar inhibition was observed in mice treated with a neutralizing mAb directed against L1 cell adhesion molecule (L1CAM), a ligand for CD24. Importantly, significant shorter patient survival was found in heparanase-high/CD24-high tumors vs. heparanase-high/CD24-low tumors for both high-grade and low-grade glioma (p = 0.02). Our results thus uncover a novel heparanase-CD24-L1CAM axis that plays a significant role in glioma tumorigenesis.
  •  
69.
  • Barczyk, K., et al. (författare)
  • Serum cytochrome c indicates in vivo apoptosis and can serve as a prognostic marker during cancer therapy
  • 2005
  • Ingår i: International Journal of Cancer. - 0020-7136. ; 116:2, s. 167-173
  • Tidskriftsartikel (refereegranskat)abstract
    • Despite significant progress in cancer therapy, the outcome of the treatment is often unfavorable. Better treatment monitoring would not only allow an individual more effective, patient-adjusted therapy, but also it would eliminate some of the side effects. Using a cytochrome c ELISA that was modified to increase sensitivity, we demonstrate that serum cytochrome c is a sensitive apoptotic marker in vivo reflecting therapy-induced cell death burden. Furthermore, increased serum cytochrome c level is a negative prognostic marker. Cancer patients whose serum cytochrome c level was normal 3 years ago have a twice as high probability to be still alive, as judged from sera samples collected for years, analyzed recently and matched with survival data. Moreover, we show that serum cytochrome c and serum LDH-activity reflect different stages and different forms of cell death. Cellular cytochrome c release is specific for apoptosis, whereas increased LDH activity is an indicator of (secondary) necrosis. Whereas serum LDH activity reflects the "global" degree of cell death over a period of time, the sensitive cytochrome c-based method allows confirmation of the individual cancer therapy-induced and spontaneous cell death events. The combination of cytochrome c with tissue-specific markers may provide the foundation for precise monitoring of apoptosis in vivo, by "lab-on-the-chip" technology. (c) 2005 Wiley-Liss, Inc.
70.
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (84)
Typ av publikation
tidskriftsartikel (989)
konferensbidrag (15)
forskningsöversikt (3)
Typ av innehåll
refereegranskat (956)
övrigt vetenskapligt (60)
Författare/redaktör
Trichopoulou, Antoni ... (123)
Overvad, Kim (120)
Tumino, Rosario (119)
Riboli, Elio (118)
Boeing, Heiner (111)
Kaaks, Rudolf (99)
visa fler...
Khaw, Kay-Tee (96)
Palli, Domenico (91)
Tjønneland, Anne (85)
Tjonneland, Anne (85)
Boutron-Ruault, Mari ... (84)
Sánchez, Maria-José (79)
Weiderpass, Elisabet ... (76)
Panico, Salvatore (75)
Vineis, Paolo (65)
Bueno-de-Mesquita, H ... (62)
Barricarte, Aurelio (61)
Clavel-Chapelon, Fra ... (53)
Ardanaz, Eva (53)
Trichopoulos, Dimitr ... (52)
Travis, Ruth C (51)
Hemminki, Kari, (51)
Chirlaque, Maria-Dol ... (48)
Jenab, Mazda (48)
Peeters, Petra H (47)
Hallmans, Göran, (47)
Dorronsoro, Miren (47)
Manjer, Jonas (46)
Wareham, Nick (46)
Olsen, Anja (45)
Sacerdote, Carlotta (45)
Larranaga, Nerea (44)
Rinaldi, Sabina (44)
Lund, Eiliv (42)
Key, Timothy J (42)
Peeters, Petra H. M. (41)
Lagiou, Pagona (40)
Stattin, Pär, (38)
Tjonneland, A (36)
Skeie, Guri (36)
Dillner, Joakim, (35)
Krogh, Vittorio (34)
González, Carlos A (34)
Mattiello, Amalia (33)
Romieu, Isabelle (32)
Lukanova, Annekatrin (32)
Amiano, Pilar (31)
Adami, HO, (31)
Quiros, JR (30)
Kühn, Tilman (30)
visa färre...
Lärosäte
Karolinska Institutet (585)
Lunds universitet (405)
Umeå universitet (219)
Uppsala universitet (151)
Göteborgs universitet (59)
Linköpings universitet (34)
visa fler...
Örebro universitet (25)
Stockholms universitet (9)
Mälardalens högskola (7)
Chalmers tekniska högskola (5)
Södertörns högskola (3)
Kungliga Tekniska Högskolan (2)
Malmö universitet (2)
Högskolan i Skövde (2)
Sveriges Lantbruksuniversitet (2)
Högskolan Kristianstad (1)
Mittuniversitetet (1)
Högskolan i Halmstad (1)
visa färre...
Språk
Engelska (999)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (666)
Naturvetenskap (8)
Lantbruksvetenskap (3)
Teknik (2)
Samhällsvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy